mTOR is constitutively activated in 25% of ESCC patients (16), and therapeutic targeting of the mTOR signaling cascade has increased survival rates and improved quality of life in ESCC patients (26). This evidence concerns the gene MTOR and esophageal squamous cell carcinoma.